Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Robert-Guroff Website

Marjorie Robert-Guroff, Ph.D.

Selected Publications

1)  Tuero I, Robert-Guroff M.
Challenges in mucosal HIV vaccine development: Lessons from non-human primate models.
Viruses. 2014.
In Press. [Journal]
2)  Qureshi H, Genesca M, Fritts L, McChesney M, Robert-Guroff M, Miller C.
Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques.
PLoS One. 2014.
In Press. [Journal]
3)  Moniuszko M, Liyanage NP, Doster MN, Parks RW, Grubczak K, Lipinska D, McKinnon K, Brown C, Hirsch V, Vaccari M, Gordon S, Pegu P, Fenizia C, Flisiak R, Grzeszczuk A, Dabrowska M, Robert-Guroff M, Silvestri G, Stevenson M, McCune J, Franchini G.
Glucocorticoid Treatment at Moderate Doses of SIVmac251-Infected Rhesus Macaques Decreases the Frequency of Circulating CD14(+)CD16(++) Monocytes But Does Not Alter the Tissue Virus Reservoir.
AIDS Res. Hum. Retroviruses. [Epub ahead of print], 2014.
4)  Vargas-Inchaustegui DA, Tuero I, Mohanram V, Musich T, Pegu P, Valentin A, Sui Y, Rosati M, Bear J, Venzon DJ, Kulkarni V, Alicea C, Pilkington GR, Liyanage NP, Demberg T, Gordon SN, Wang Y, Hogg AE, Frey B, Patterson LJ, DiPasquale J, Montefiori DC, Sardesai NY, Reed SG, Berzofsky JA, Franchini G, Felber BK, Pavlakis GN, Robert-Guroff M.
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.
Clin. Immunol. [Epub ahead of print], 2014.
5)  Mohanram V, Demberg T, Tuero I, Vargas-Inchaustegui D, Pavlakis GN, Felber BK, Robert-Guroff M.
Improved flow-based method for HIV/SIV envelope-specific memory B-cell evaluation in rhesus macaques.
J. Immunol. Methods. [Epub ahead of print], 2014.
6)  Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal DN, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM.
Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.
Retrovirology. 11: 8, 2014.
7)  Demberg T, Mohanram V, Venzon D, Robert-Guroff M.
Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV Rhesus macaque model.
Clin. Immunol. [Epub ahead of print], 2014.
8)  Thomas MA, Demberg T, Vargas-Inchaustegui DA, Xiao P, Tuero I, Venzon D, Weiss D, Treece J, Robert-Guroff M.
Rhesus macaque rectal and duodenal tissues exhibit B-cell sub-populations distinct from peripheral blood that continuously secrete antigen-specific IgA in short-term explant cultures.
Vaccine. 32: 872-80, 2014.
9)  Vaccari M, Halwani R, Patterson LJ, Boasso A, Beal J, Tryniszewska E, Hryniewicz A, Venzon D, Haddad EK, El-Far M, Rosati M, Pavlakis GN, Felber BK, Al-Muhsen S, Robert-Guroff M, Sekaly RP, Franchini G.
Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.
J. Virol. 87: 3526-37, 2013.
10)  Thomas MA, Song R, Demberg T, Vargas-Inchaustegui DA, Venzon D, Robert-Guroff M.
Effects of the Deletion of Early Region 4 (E4) Open Reading Frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on Virus-Host Cell Interaction, Transgene Expression, and Immunogenicity of Replicating Adenovirus HIV Vaccine Vectors.
PLoS ONE. 8: e76344, 2013.
11)  Vargas-Inchaustegui DA, Robert-Guroff M.
Fc Receptor-Mediated Immune Responses: New Tools But Increased Complexity in HIV Prevention.
Curr. HIV Res. 11: 407-20, 2013.
12)  Campbell CT, Llewellyn SR, Damberg T, Morgan IL, Robert-Guroff M, Gildersleeve JC.
High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge.
PLoS ONE. 8: e75302, 2013.
13)  Vargas-Inchaustegui DA, Xiao P, Hogg AE, Demberg T, McKinnon K, Venzon D, Brocca-Cofano E, Dipasquale J, Lee EM, Hudacik L, Pal R, Sui Y, Berzofsky JA, Liu L, Langermann S, Robert-Guroff M.
Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.
Virology. 447: 274-84, 2013.
14)  Demberg T, Brocca-Cofano E, Kuate S, Aladi S, Vargas-Inchaustegui DA, Venzon D, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Dipasquale J, Ruprecht RM, Montefiori DC, Srivastava I, Barnett SW, Robert-Guroff M.
Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques.
Virology. 440: 210-221, 2013.
15)  Demberg T, Robert-Guroff M.
Controlling the HIV/AIDS epidemic: current status and global challenges.
Front Immunol. 3: 250, 2012.
16)  Demberg T, Brocca-Cofano E, Xiao P, Venzon D, Vargas-Inchaustegui D, Lee EM, Kalisz I, Kalyanaraman VS, Dipasquale J, McKinnon K, Robert-Guroff M.
Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques.
J. Virol. 86: 12591-604, 2012.
17)  Rasmussen RA, Siddappa NB, Lakhashe SK, Watkins J, Villinger F, Ibegbu C, Florese RH, Robert-Guroff M, Montefiori DC, Forthal DN, O'Connor D, Ruprecht RM.
High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia.
AIDS. 26: 149-55, 2012.
18)  Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.
Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
J. Virol. 86: 2239-50, 2012.
19)  Vargas-Inchaustegui DA, Xiao P, Tuero I, Patterson LJ, Robert-Guroff M.
NK and CD4+ T Cell Cooperative Immune Responses Correlate with Control of Disease in a Macaque Simian Immunodeficiency Virus Infection Model.
J Immunol. 189: 1878-85, 2012.
20)  Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, Zhao J, DiPasquale J, Fenizia C, Lee EM, Kalisz I, Kalyanaraman VS, Pal R, Montefiori D, Keele BF, Robert-Guroff M.
Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.
J. Virol. 86: 4644-57, 2012.
21)  Patterson LJ, Kuate S, Daltabuit-Test M, Li Q, Xiao P, McKinnon K, Dipasquale J, Cristillo A, Venzon D, Haase A, Robert-Guroff M.
Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Vectors Efficiently Prime SIV-Specific Systemic and Mucosal Immune Responses by Targeting Myeloid Dendritic Cells and Persisting in Rectal Macrophages, Regardless of Immunization Route.
Clin. Vaccine Immunol. 19: 629-37, 2012.
22)  Gordon SN, Kines RC, Kutsyna G, Ma ZM, Hryniewicz A, Roberts JN, Fenizia C, Hidajat R, Brocca-Cofano E, Cuburu N, Buck CB, Bernardo ML, Robert-Guroff M, Miller CJ, Graham BS, Lowy DR, Schiller JT, Franchini G.
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.
J. Immunol. 188: 714-23, 2012.
23)  Brocca-Cofano E, Xiao P, Robert-Guroff M.
HIV Envelope specific antibody and vaccine efficacy. In: HIV and AIDS - Updates on Biology, Immunology, epidemiology and Treatment Strategies.
ISBN 978-953-307-665-2: Intech Open Access publisher; 2011. p. 257-280 [Book Chapter]
24)  Vargas-Inchaustegui DA, Demberg T, Robert-Guroff M.
A CD8alpha(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.
Immunology. 134: 326-40, 2011.
25)  George J, Cofano EB, Lybarger E, Louder M, Lafont BA, Mascola JR, Robert-Guroff M, Mattapallil JJ.
Early Short-Term Antiretroviral Therapy Is Associated with a Reduced Prevalence of CD8(+)FoxP3(+) T Cells in Simian Immunodeficiency Virus-Infected Controller Rhesus Macaques.
AIDS Res Hum Retroviruses. 27: 763-775, 2011.
26)  Palermo RE, Patterson LJ, Aicher LD, Korth MJ, Robert-Guroff M, Katze MG.
Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy.
J. Virol. 85: 1099-116, 2011.
27)  Lakhashe SK, Velu V, Sciaranghella G, Siddappa NB, Dipasquale JM, Hemashettar G, Yoon JK, Rasmussen RA, Yang F, Lee SJ, Montefiori DC, Novembre FJ, Villinger F, Amara RR, Kahn M, Hu SL, Li S, Li Z, Frankel FR, Robert-Guroff M, Johnson WE, Lieberman J, Ruprecht RM.
Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges.
Vaccine. 29: 5611-22, 2011.
28)  Patterson LJ, Daltabuit-Test M, Xiao P, Zhao J, Hu W, Wille-Reece U, Brocca-Cofano E, Kalyanaraman VS, Kalisz I, Whitney S, Lee EM, Pal R, Montefiori DC, Dandekar S, Seder R, Roederer M, Wiseman RW, Hirsch V, Robert-Guroff M.
Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.
Virology. 411: 87-102, 2011.
29)  Demberg T, Ettinger AC, Aladi S, McKinnon K, Kuddo T, Venzon D, Patterson LJ, Phillips TM, Robert-Guroff M.
Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.
Vaccine. 29: 6017-28, 2011.
30)  Fenizia C, Keele BF, Nichols D, Cornara S, Binello N, Vaccari M, Pegu P, Robert-Guroff M, Ma Z, Miller CJ, Venzon D, Hirsch V, Franchini G.
TRIM5alpha does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure.
J. Virol. 85: 12399-409, 2011.
31)  Bialuk J, Whitney S, Andresen V, Florese R, Nacsa J, Cecchinato V, Valeri V, Heraud J, Gordon S, Parks R, Montefiori D, Venzon D, Demberg T, Robert-Guroff M, Landucci G, Forthal D, Franchini G.
Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120 mediate antibody-dependent virus inhibition in macaques.
Vaccine. 30: 78-94, 2011.
32)  Brocca-Cofano E, McKinnon K, Demberg T, Venzon D, Hidajat R, Xiao P, Daltabuit-Test M, Patterson LJ, Robert-Guroff M.
Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia.
Vaccine. 29: 3310-9, 2011.
33)  Hidajat R, Kuate S, Venzon D, Kalyanaraman V, Kalisz I, Treece J, Lian Y, Barnett SW, Robert-Guroff M.
Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.
Vaccine. 28: 3963-71, 2010.
34)  Cafaro A, Bellino S, Titti F, Maggiorella MT, Sernicola L, Wiseman RW, Venzon D, Karl JA, O'Connor D, Monini P, Robert-Guroff M, Ensoli B.
Impact of Viral Dose and Major Histocompatibility Complex Class IB Haplotype on Viral Outcome in Tat-vaccinated Mauritian Cynomolgus Monkeys upon Challenge with SHIV89.6P.
J Virol. 84: 8953-8958, 2010.
35)  Patel V, Valentin A, Kulkarni V, Rosati M, Bergamaschi C, Jalah R, Alicea C, Minang JT, Trivett MT, Ohlen C, Zhao J, Robert-Guroff M, Khan AS, Draghia-Akli R, Felber BK, Pavlakis GN.
Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.
Vaccine. 28: 4827-36, 2010.
36)  Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, Hidajat R, Demberg T, Robert-Guroff M.
Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
J. Virol. 84: 7161-73, 2010.
37)  Robert-Guroff M, Nabel GJ, Shiver JW.
Levine MM, eds.
Replication-defective and competent adenovirus recombinants as vaccine vectors. In: New Generation Vaccines, 4th Edition.
New York: Informa Healthcare; 2009. p. 352-360 [Book Chapter]
38)  Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, Summers LE, Venzon D, Cafaro A, Ensoli B, Robert-Guroff M.
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.
J. Immunol. 182: 3718-27, 2009.
39)  Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, Montefiori DC, Robert-Guroff M.
Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.
J. Virol. 83: 791-801, 2009.
40)  Demberg T, Robert-Guroff M.
Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.
Int. Rev. Immunol. 28: 20-48, 2009.
41)  Florese RH, Wiseman RW, Venzon D, Karl JA, Demberg T, Larsen K, Flanary L, Kalyanaraman VS, Pal R, Titti F, Patterson LJ, Heath MJ, O'Connor DH, Cafaro A, Ensoli B, Robert-Guroff M.
Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.
Vaccine. 26: 3312-21, 2008.
42)  Patterson LJ, Beal J, Demberg T, Florese RH, Malkevich N, Venzon D, Aldrich K, Richardson E, Kalyanaraman VS, Kalisz I, Lee EM, Montefiori DC, Robey FA, Robert-Guroff M.
Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.
Virology. 374: 322-37, 2008.
43)  Patterson LJ, Robert-Guroff M.
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.
Expert Opin Biol Ther. 8: 1347-63, 2008.
44)  Demberg T, Boyer JD, Malkevich N, Patterson LJ, Venzon D, Summers EL, Kalisz I, Kalyanaraman VS, Lee EM, Weiner DB, Robert-Guroff M.
Sequential priming with SIV DNA vaccines, with or without encoded cytokines, and a replicating Ad-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.
J. Virol. 82: 10911-10921, 2008.
45)  Bogers WM, Davis D, Baak I, Kan E, Hofman S, Sun Y, Mortier D, Lian Y, Oostermeijer H, Fagrouch Z, Dubbes R, van der Maas M, Mooij P, Koopman G, Verschoor E, Langedijk JP, Zhao J, Brocca-Cofano E, Robert-Guroff M, Srivastava I, Barnett S, Heeney JL.
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.
Virology. 382: 217-25, 2008.
46)  Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, Self S, Corey L.
The use of nonhuman primate models in HIV vaccine development.
PLoS Med. 5: e173, 2008.
47)  Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Venzon D, Grant R, Patterson LJ, Korioth-Schmitz B, Buzby A, Dombagoda D, Montefiori DC, Letvin NL, Cafaro A, Ensoli B, Robert-Guroff M.
A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
J. Virol. 81: 3414-27, 2007.
48)  Zhou Q, Hidajat R, Peng B, Venzon D, Aldrich MK, Richardson E, Lee EM, Kalyanaraman VS, Grimes G, Gomez-Roman VR, Summers LE, Malkevich N, Robert-Guroff M.
Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).
Vaccine. 25: 8021-35, 2007.
49)  Florese RH, Robert-Guroff M.
Non-neutralizing antibodies and vaccine-induced protection against HIV.
Future HIV Therapy. 1: 259-71, 2007.
50)  Titti F, Cafaro A, Ferrantelli F, Tripiciano A, Moretti S, Caputo A, Gavioli R, Ensoli F, Robert-Guroff M, Barnett S, Ensoli B.
Problems and emerging approaches in HIV/AIDS vaccine development.
Expert Opin Emerg Drugs. 12: 23-48, 2007.
51)  Robert-Guroff M.
Replicating and non-replicating viral vectors for vaccine development.
Curr. Opin. Biotechnol. 18: 546-56, 2007.
52)  Gomez-Roman VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M.
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.
J. Immunol. Methods. 308: 53-67, 2006.
53)  Gomez-Roman VR, Florese RH, Peng B, Montefiori DC, Kalyanaraman VS, Venzon D, Srivastava I, Barnett SW, Robert-Guroff M.
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.
J. Acquir. Immune Defic. Syndr. 43: 270-7, 2006.
54)  Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, Florese RH, Kalyanaraman VS, Pal R, Lee EM, Zhao J, Cristillo A, Robert-Guroff M.
Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIV(mac251) rectal challenge: Role of SIV-specific CD8+ T cell responses.
Virology. 353: 83-98, 2006.
55)  Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M.
Evaluation of Passively Transferred, Nonneutralizing Antibody-Dependent Cellular Cytotoxicity-Mediating IgG in Protection of Neonatal Rhesus Macaques against Oral SIVmac251 Challenge.
J. Immunol. 177: 4028-36, 2006.
56)  Gomez-Roman VR, Grimes GJ, Potti GK, Peng B, Demberg T, Gravlin L, Treece J, Pal R, Lee EM, Alvord WG, Markham PD, Robert-Guroff M.
Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques.
Vaccine. 24: 5064-72, 2006.
57)  Peng B, Voltan R, Cristillo AD, Alvord WG, Davis-Warren A, Zhou Q, Murthy KK, Robert-Guroff M.
Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity.
AIDS. 20: 2149-57, 2006.
58)  Rosati M, von Gegerfelt A, Roth P, Alicea C, Valentin A, Robert-Guroff M, Venzon D, Montefiori DC, Markham P, Felber BK, Pavlakis GN.
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.
J Virol. 79: 8480-92, 2005.
59)  Zhao J, Voltan R, Peng B, Davis-Warren A, Kalyanaraman VS, Alvord WG, Aldrich K, Bernasconi D, Buttò S, Cafaro A, Ensoli B, Robert-Guroff M.
Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Virology. 342: 1-12, 2005.
60)  Pinczewski J, Zhao J, Malkevitch N, Patterson LJ, Aldrich K, Alvord WG, Robert-Guroff M.
Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE.
Viral Immunol. 18: 236-43, 2005.
61)  Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, Venzon D, Zhao J, Kan E, Rowell TJ, Murthy KK, Srivastava I, Barnett SW, Robert-Guroff M.
Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.
J Virol. 79: 10200-10209, 2005.
62)  Edghill-Smith Y, Bray M, Whitehouse CA, Miller D, Mucker E, Manischewitz J, King LR, Robert-Guroff M, Hryniewicz A, Venzon D, Meseda C, Weir J, Nalca A, Livingston V, Wells J, Lewis MG, Huggins J, Zwiers SH, Golding H, Franchini G.
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.
J Infect Dis. 191: 372-81, 2005.
63)  Gomez-Roman VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M.
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251.
J Immunol. 174: 2185-9, 2005.
64)  Malkevitch NV, Robert-Guroff M.
A call for replicating vector prime-protein boost strategies in HIV vaccine design.
Expert Rev Vaccines. 3 Suppl 1: S105-17, 2004.
65)  Malkevitch N, Rohne D, Pinczewski J, Aldrich K, Kalyanaraman VS, Letvin NL, Robert-Guroff M.
Evaluation of combination DNA/replication competent Ad-SIV recombinant immunization regimens in rhesus macaques.
AIDS Res. Human Retroviruses. 20: 235-244, 2004.
66)  Patterson L, Peng B, Nan X, Robert-Guroff M.
Live adenovirus recombinants as vaccine vectors.
In: Levine MM, Kaper JB, Rappuoli R, Liu M, Good MF, Eds. New Generation Vaccines, 3rd Edition: New York, Marcel Dekker, Inc.; 325-335, 2004.
67)  Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gómez-Román VR, Wang L, Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M.
Protection against mucosal SIVmac251 challenge using replicating adenovirus-SIV multi-gene vaccine priming and subunit boosting.
J Virol. 78: 2212-2221, 2004.
68)  Malkevitch N, Patterson LJ, Aldrich K, Richardson E, Alvord WG, Robert-Guroff M.
A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in mamu-A*01 rhesus macaques.
J Immunol. 170: 4281-9, 2003.
69)  Gomez-Roman VR, Robert-Guroff M.
Adenoviruses as vectors for HIV vaccines.
AIDS Reviews. 5: 178-185, 2003.
70)  Zhao J, Lou Y, Pinczewski J, Malkevitch N, Aldrich K, Kalyanaraman VS, Venzon D, Peng B, Patterson LJ, Edghill-Smith Y, Woodward R, Pavlakis GN, Robert-Guroff M.
Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants.
Vaccine. 21: 4022-35, 2003.
71)  Nan X, Peng B, Hahn TW, Richardson E, Lizonova A, Kovesdi I, Robert-Guroff M.
Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus.
Gene Ther. 10: 326-36, 2003.
72)  Zhao J, Pinczewski J, Gómez-Román VR, Venzon D, Kalyanaraman VS, Markham PD, Aldrich K, Moake M, Montefiori DC, Lou Y, Pavlakis GN, Robert-Guroff M.
Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
J Virol. 77: 8354-65, 2003.
73)  Voltan R, Robert-Guroff M.
Live recombinant vectors for AIDS vaccine development.
Curr Mol Med. 3: 273-84, 2003.
74)  Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, Munch C, Leonard M, Richardson E, Aldrich K, Kalyanaraman VS, Pavlakis GN, Robert-Guroff M.
Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.
J Virol. 77: 8607-20, 2003.
75)  Edghill-Smith YY, Aldrich K, Zhao J, Pinczewski J, Kalyanaraman VS, Johnson M, Heyliger A, Perrin RP, Woodward R, Robert-Guroff M.
Effects of intestinal survival surgery on systemic and mucosal immune responses in SIV-infected rhesus macaques.
J Med Primatol. 31: 313-22, 2002.
76)  Robert-Guroff M.
HIV regulatory and accessory proteins: new targets for vaccine development.
DNA Cell Biol. 21: 597-8, 2002.
77)  Patterson LJ, Prince GA, Richardson E, Alvord WG, Kalyan N, Robert-Guroff M.
Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion.
Virology. 292: 107-13, 2002.
78)  Patterson LJ, Malkevitch N, Zhao J, Peng B, Robert-Guroff M.
Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.
DNA Cell Biol. 21: 627-35, 2002.
79)  Peng B, Voltan R, Lim L, Edghill-Smith Y, Phogat S, Dimitrov DS, Arora K, Leno M, Than S, Woodward R, Markham PD, Cranage M, Robert-Guroff M.
Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication.
J Virol. 76: 6016-26, 2002.
80)  Patterson LJ, Robey F, Muck A, Van Remoortere K, Aldrich K, Richardson E, Alvord WG, Markham PD, Cranage M, Robert-Guroff M.
A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge.
AIDS Res Hum Retroviruses. 17: 837-49, 2001.
81)  Robey FA, Robert-Guroff M.
A defined conformational epitope from the C4 domain of HIV type 1 glycoprotein 120: anti-cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells.
AIDS Res Hum Retroviruses. 17: 533-41, 2001.
82)  Peng B, Robert-Guroff M.
Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation.
Immunol Lett. 78: 195-200, 2001.
83)  Robert-Guroff M, Buehring G.
Goedert J, eds.
In pursuit of a human breast cancer virus: from mouse to human. In: Infectious Causes of Cancer: Targets for Intervention.
Totowa: Humana Press Inc.; 2000. p. 475-487 [Book Chapter]
84)  Leno M, Kowalski M, Robert-Guroff M.
CD8 T cell anti-HIV activity as a complementary protective mechanism in vaccinated chimpanzees.
AIDS. 14: 893-4, 2000.
85)  Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M.
Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.
AIDS. 14: 2445-55, 2000.
86)  Robert-Guroff M.
IgG surfaces as an important component in mucosal protection.
Nat Med. 6: 129-30, 2000.
87)  Margolis L, Glushakova S, Chougnet C, Shearer G, Markham P, Robert-Guroff M, Benveniste R, Miller CJ, Cranage M, Hirsch V, Franchini G.
Replication of simian immunodeficiency virus (SIV) in ex vivo lymph nodes as a means to assess susceptibility of macaques in vivo.
Virology. 275: 391-7, 2000.
88)  Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, Sinangil F, Alipanah S, Murthy SC, Chanda PK, Nigida SM, Markham PD, Zolla-Pazner S, Steimer K, Wade M, Reitz MS, Arthur LO, Mizutani S, Davis A, Hung PP, Gallo RC, Eichberg J, Robert-Guroff M.
Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization.
Nat. Med. 3: 651-8, 1997.
89)  Reitz MS, Wilson C, Naugle C, Gallo RC, Robert-Guroff M.
Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.
Cell. 54: 57-63, 1988.
90)  Robert-Guroff M, Brown M, Gallo RC.
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.
Nature. 316: 72-4, 1985.
91)  Robert-Guroff M, Nakao Y, Notake K, Ito Y, Sliski A, Gallo RC.
Natural antibodies to human retrovirus HTLV in a cluster of Japanese patients with adult T cell leukemia.
Science. 215: 975-8, 1982.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/5/2014.